Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.65 |
| ▸ | CNR2 | P34972 | 3/20 | 0.65 |
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18670586 | 1.00 | CNR1 (0.65) | CNR1CNR2FAAHALDH1A1HPGD | |
| SCHEMBL886853 | 1.00 | CNR1 (0.65) | CNR1CNR2FAAHALDH1A1HPGD | |
| SCHEMBL7211379 | 1.00 | CNR1 (0.65) | CNR1CNR2FAAHALDH1A1HPGD | |
| SCHEMBL886852 | 1.00 | CNR1 (0.65) | CNR1CNR2FAAHALDH1A1HPGD | |
| SCHEMBL9951849 | 1.00 | CNR1 (0.65) | CNR1CNR2FAAHALDH1A1HPGD | |
| SCHEMBL6665064 | 1.00 | CNR1 (0.65) | CNR1CNR2FAAHALDH1A1HPGD | |
| SCHEMBL16400196 | 1.00 | CNR1 (0.65) | CNR1CNR2FAAHALDH1A1HPGD | |
| SCHEMBL5884581 | 1.00 | CNR1 (0.65) | CNR1CNR2FAAHALDH1A1HPGD | |
| SCHEMBL15364951 | 1.00 | CNR1 (0.65) | CNR1CNR2FAAHALDH1A1HPGD | |
| SCHEMBL7638596 | 0.98 | CNR1 (0.67) | CNR1CNR2FAAHALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694699-A2 | COMPOSITIONS AND METHODS OF CONTROLLING MAMMALIAN SATIETY | VitaKey Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| WO-2024216228-A2 | COMPOSITIONS AND METHODS OF CONTROLLING MAMMALIAN SATIETY | VITAKEY INC. (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024124354-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PAIN OR OTHER DISORDERS | AIMA INC. (CA) | 2024-06-20 | — | — | WO | claimed |
| EP-4380555-A1 | COMPOSITION COMPRISING MANNOSE, N-ACETYLCYSTEINE AND AT LEAST ONE ENDOCANNABINOID AND ITS USE FOR THE TREATMENT OF URIRNARY TRACT INFECTIONS | Agave S.r.l. (IT) | 2024-06-12 | — | — | EP | claimed |
| WO-2023012657-A1 | COMPOSITION COMPRISING MANNOSE, N-ACETYLCYSTEINE AND AT LEAST ONE ENDOCANNABINOID AND ITS USE FOR THE TREATMENT OF URIRNARY TRACT INFECTIONS | AGAVE S.R.L. (IT) | 2023-02-09 | — | — | WO | claimed |
| WO-2022006187-A1 | METHODS OF USING CANNABINOID COMPOSITIONS FOR INDUCING AND PROMOTING SLEEP | NP PHARMA HOLDINGS, LLC (US) | 2022-01-06 | — | — | WO | claimed |
| US-20210401794-A1 | Methods of Using Cannabinoid Compositions for Inducing and Promoting Sleep | NP PHARMA HOLDINGS. LLC | 2021-12-30 | — | — | US | claimed |
| EP-3773526-A1 | COMPOSITION FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES | Sochim International SpA (IT) | 2021-02-17 | — | — | EP | claimed |
| WO-2019197967-A1 | COMPOSITION FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES | SOCHIM INTERNATIONAL S.P.A. (IT) | 2019-10-17 | — | — | WO | claimed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| US-20260102502-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | UNIV JOHNS HOPKINS (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4380555-B1 | COMPOSITION COMPRISING D-MANNOSE, N-ACETYLCYSTEINE AND PALMITOYLETHANOLAMIDE AND ITS USE FOR THE TREATMENT OF URIRNARY TRACT INFECTIONS | AGAVE S R L (IT) | 2026-03-25 | — | — | EP | disclosed |
| EP-4694699-A2 | COMPOSITIONS AND METHODS OF CONTROLLING MAMMALIAN SATIETY | VitaKey Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12357604-B2 | Topical formulations of cannabinoids and use thereof in the treatment of pain | INMED PHARMACEUTICALS INC. (CA) | 2025-07-15 | — | — | US | disclosed |
| EP-4577247-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | The Johns Hopkins University (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20090163557-A1 | Cannabinergic Lipid Ligands | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-06-25 | — | — | US | disclosed |
| WO-2008100977-A2 | CARBAMATES THERAPEUTIC RELEASE AGENTS AS AMIDASE INHIBITORS | N.V. ORGANON (NL) | 2008-08-21 | — | — | WO | disclosed |
| EP-1812378-A2 | CANNABINERGIC LIPID LIGANDS | University of Connecticut (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006044381-A2 | CANNABINERGIC LIPID LIGANDS | UNIVERSITY OF CONNECTICUT (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060058222-A1 | Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders | MILLER LANDON C | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058222-A1 | Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders | OPRL1, OPRK1, OPRM1 | CNR1 6/4885CNR2 5/4885FAAH 7/4885 |
| US-12357604-B2 | Topical formulations of cannabinoids and use thereof in the treatment of pain | CNR2, CNR1, LCAT | CNR1 2/4885CNR2 1/4885FAAH 8/4885 |
| US-20260102502-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885FAAH 11/4885 |
| US-20090163557-A1 | Cannabinergic Lipid Ligands | FAAH, FAAH2, CNR2 | CNR1 4/4885CNR2 3/4885FAAH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.